Ben Neel (L) and Raj Chopra

Up­dat­ed: New Ap­ple Tree biotech emerges with an­ti­bod­ies that might pair with Am­gen, Mi­rati's KRAS drugs

Ap­ple Tree Part­ners is out Mon­day with a new biotech from the labs of NYU Lan­gone Health that aims to tack­le drug re­sis­tance in can­cer.

Aethon Ther­a­peu­tics will get $25 mil­lion from the VC firm, and an­oth­er $5 mil­lion from New York Uni­ver­si­ty and oth­er in­vestors, the New York-based biotech said Mon­day.

The fledg­ling start­up is work­ing off a so-called HapIm­mune im­munother­a­py plat­form from the labs of Shohei Koide and Ben­jamin Neel at NYU’s Perl­mut­ter Can­cer Cen­ter. The two re­searchers be­gan pon­der­ing the idea about three and a half years ago, Neel told End­points News, and they came to Ap­ple Tree’s head of on­col­o­gy Raj Chopra about a year ago to form the com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.